Related Experiment Video
Updated: Oct 28, 2025
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
Published on: October 3, 2010
Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse
Stacey Richardson1, Rebecca M Hill1, Christopher Kui1
1Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University Centre for Cancer, Newcastle upon Tyne, UK.
Background:
Less than 5% of medulloblastoma (MB) patients survive following failure of contemporary radiation-based therapies. Understanding the molecular drivers of medulloblastoma relapse (rMB) will be essential to improve outcomes. Initial genome-wide investigations have suggested significant genetic divergence of the relapsed disease.
Methods:
We undertook large-scale integrated characterization of the molecular features of rMB-molecular subgroup, novel subtypes, copy number variation (CNV), and driver gene mutation. 119 rMBs were assessed in comparison with their paired diagnostic samples (n = 107), alongside an independent reference cohort sampled at diagnosis (n = 282). rMB events were investigated for association with outcome post-relapse in clinically annotated patients (n = 54).
Results:
Significant genetic evolution occurred over disease-course; 40% of putative rMB drivers emerged at relapse and differed significantly between molecular subgroups. Non-infant MBSHH displayed significantly more chromosomal CNVs at relapse (TP53 mutation-associated). Relapsed MBGroup4 demonstrated the greatest genetic divergence, enriched for targetable (eg, CDK amplifications) and novel (eg, USH2A mutations) events. Importantly, many hallmark features of MB were stable over time; novel subtypes (>90% of tumors) and established genetic drivers (eg, SHH/WNT/P53 mutations; 60% of rMB events) were maintained from diagnosis. Critically, acquired and maintained rMB events converged on targetable pathways which were significantly enriched at relapse (eg, DNA damage signaling) and specific events (eg, 3p loss) predicted survival post-relapse.
Conclusions:
rMB is characterised by the emergence of novel events and pathways, in concert with selective maintenance of established genetic drivers. Together, these define the actionable genetic landscape of rMB and provide a basis for improved clinical management and development of stratified therapeutics, across disease-course.
Insights
Relapsed medulloblastoma (rMB) shows significant genetic changes, with new drivers emerging at relapse. Understanding these molecular alterations is key to developing targeted therapies for improved patient survival.
Area of Science:
- Pediatric Oncology
- Cancer Genomics
- Molecular Biology
Background:
- Medulloblastoma (MB) has poor survival rates after radiation therapy failure.
- Understanding molecular drivers of relapsed MB (rMB) is crucial for improving outcomes.
- Initial studies suggest significant genetic divergence in relapsed disease.
Purpose of the Study:
- To perform large-scale integrated molecular characterization of rMB.
- To identify novel subtypes, copy number variations (CNVs), and driver gene mutations in rMB.
- To investigate the association of rMB events with post-relapse survival.
Main Methods:
- Integrated analysis of 119 rMBs compared to paired diagnostic samples (n=107).
- Assessment of an independent diagnostic cohort (n=282).
- Investigation of rMB events in 54 clinically annotated patients for outcome association.
Main Results:
- Significant genetic evolution observed, with 40% of drivers emerging at relapse.
- Relapsed MBGroup4 showed greatest divergence, enriched for targetable events like CDK amplifications.
- Established drivers and subtypes were largely maintained, while acquired events converged on targetable pathways (e.g., DNA damage signaling).
Conclusions:
- rMB is characterized by both novel emergent events and maintained genetic drivers.
- These findings define the actionable genetic landscape of rMB.
- Provides a basis for improved clinical management and stratified therapeutics for rMB.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:23Abnormal Proliferation
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...